Loading...
Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients
Forster, M. Felip, E. Doger, B. Pousa, A. L. Carcereny, E. Bajaj, P. Church, Matt Peguero, J. Roxburgh, P. Triebel, F.
Forster, M.
Felip, E.
Doger, B.
Pousa, A. L.
Carcereny, E.
Bajaj, P.
Church, Matt
Peguero, J.
Roxburgh, P.
Triebel, F.
Citations
Altmetric:
Abstract
Background: Eftilagimod alpha (efti) is a soluble LAG-3 protein that binds to a subset
of MHC class II molecules to mediate antigen presenting cell (APC) activation and CD8
T-cell activation. The stimulation of the dendritic cell network and subsequent T cell
recruitment with efti may lead to stronger anti-tumor responses in combination than
observed with pembrolizumab alone. We hereby report initial results of the 2nd line
head and neck squamous cell carcinoma (HNSCC) part of the phase II trial
(NCT03625323).
Methods: The study has a Simon’s 2-stage design, with objective response rate (ORR)
as primary endpoint. Secondary endpoints included tolerability, disease control rate,
progression free and overall survival, PK, PD and immunogenicity. Second line, PD-X
naïve PD-L1 unselected HNSCC patients (pts) are eligible for the trial. Initially 18 pts
were recruited in stage 1, an additional 18 pts (total N¼36) recruited into stage 2 if
the pre-specified threshold of >2 responses was reached. Efti was administered as 30
mg subcutaneous injection every 2 wks for 8 cycles and then every 3 wks for 9 cycles
with pembrolizumab (200 mg intravenous infusion every 3 wks for up to 2 yrs).
Results: Between Mar 2019 and Dec 2019, 18 pts were enrolled into stage 1. The
median age was 66 yr (range 48-84) and 94 % were male. The ECOG PS 0:1 was 56 %and 44 % respectively. Pts from all PD-L1 subgroups (CPS < 1 %, 1-20%, 20 %) were
recruited. Pts received a median of 5 pembrolizumab and 7 efti administrations. All
pts in stage 1 (n¼18) were evaluable. Six pts (33 %) had a partial response (iPR), 1
patient (6 %) had a complete response and 2 (11 %) had stable disease according to
iRECIST representing an ORR (DCR) of 39 % (50 %). Threshold for opening stage 2 (> 2
responses) was met. The most common (> 10 %) adverse events (AEs) were cough
(29 %), asthenia (24 %), decreased appetite (18 %), dyspnea (18 %), fatigue (17 %),
diarrhea (15 %) and nausea (12 %). Seven (7; 41 %) pts are still on therapy and median
PFS is not yet reached.
Conclusions: Efti in combination with pembrolizumab is safe and shows encouraging
antitumor activity in 2nd line HNSCC patients.
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 91.59 KB
Keywords
Type
Meetings and Proceedings
Citation
Forster M, Felip E, Doger B, Lopez Pousa A, Carcereny E, Bajaj P, et al. 927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients. Annals of Oncology. 2020;31:S667-S.